Cardinal Health Is Getting Pummeled on Mixed Results — Here's Our Plan for Stock

Why It Matters

The results highlight Cardinal Health’s ability to generate strong cash flow despite revenue pressure, while tariff‑related profit erosion underscores a key risk for investors evaluating the drug‑distribution sector.

Key Takeaways

• Revenue rose 11% to $60.94 billion, missing consensus.
• Adjusted EPS $3.17 beat $2.79 estimate.
• Free cash flow $3.3‑$3.7 billion, three times Street view.
• Global Medical Products profit fell 35% due to tariffs.
• Full‑year earnings outlook raised to $10.70‑$10.80 per share.

Pulse Analysis

Cardinal Health’s first‑quarter report underscores a classic earnings‑mix dilemma: top‑line growth outpaced analyst forecasts, yet the miss in total revenue sparked a sharp sell‑off. The 11% YoY increase to $60.94 billion reflects robust demand for specialty and brand pharmaceuticals, especially GLP‑1 obesity treatments, but the shortfall against the $61.7 billion consensus signaled pricing pressure and a softer sales mix. Meanwhile, adjusted earnings per share of $3.17 comfortably beat the $2.79 consensus, and free cash flow surged to $3.3‑$3.7 billion—about three times the Street’s estimate—providing a cushion that helped temper investor panic.

Segment dynamics paint a more nuanced picture. Pharmaceutical and Specialty Solutions delivered 11% revenue growth, driven by a 30%+ surge in GLP‑1‑related obesity drugs, yet fell shy of the $57.56 billion estimate. The Global Medical Products and Distribution unit posted flat revenue and a 35% profit decline, largely attributable to higher tariffs and lower distribution volumes, highlighting supply‑chain vulnerabilities. Conversely, the “Other” segment—comprising Nuclear and Precision Health, at‑Home Solutions, and OptiFreight Logistics—expanded 31% YoY, outpacing expectations and showcasing the highest margin potential within Cardinal’s portfolio.

Looking ahead, the company’s revised FY2026 earnings guidance of $10.70‑$10.80 per share, with only $0.13 of the midpoint lift tied to operational performance, signals reliance on tax benefits, share repurchases, and lower non‑GAAP tax rates. The raised free cash flow outlook and improved segment‑profit growth targets suggest management is confident in cost‑optimization and brand‑centric strategies. However, the ongoing tariff exposure and a stock price hovering near its 200‑day moving average keep the upside limited, prompting a cautious stance from analysts despite the oversold technical reading.